Bridgeway Capital Management, LLC Terns Pharmaceuticals, Inc. Transaction History

Bridgeway Capital Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$4.7 - $8.55 $109,040 - $198,360	-23,200 Reduced 45.76%	27,500 $138,000
Q1 2023 May 15, 2023	SELL	$7.91 - $12.0 $332,220 - $504,000	-42,000 Reduced 45.31%	50,700 $600,000
Q4 2022 Feb 14, 2023	BUY	$4.62 - $10.18 $107,184 - $236,176	23,200 Added 33.38%	92,700 $943,000
Q3 2022 Nov 14, 2022	BUY	$1.87 - $6.42 $44,880 - $154,080	24,000 Added 52.75%	69,500 $409,000
Q2 2022 Aug 15, 2022	SELL	$1.5 - $3.0 $25,800 - $51,600	-17,200 Reduced 27.43%	45,500 $113,000
Q1 2022 May 16, 2022	SELL	$2.83 - $6.7 $92,824 - $219,760	-32,800 Reduced 34.35%	62,700 $186,000
Q4 2021 Feb 14, 2022	BUY	$5.65 - $10.73 $539,575 - $1.02 Million	95,500 New	95,500 $675,000

167

78.3M

580K

454K

Ticker TERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,613,800
Market Cap $220M
Description
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgeway Capital Management, LLC with notifications on news.